Safety Data Sheet

Pharma Source DIRECT

Version: 1.0
Issued 20 Aug 2026

1. Identification

Product Identifier Testosterone Propionate

Other means of identification

Internal item number 82393-0603

CAS number 57-85-2

Synonyms

Chemical name Androst-4-en-3-one, 17-(1-oxopropoxy)-, (17beta)-

Relevant use and restrictions: No further information available.

Application of substance: Active pharmaceutical ingredient.

Manufacturer/Supplier information

Company name Pharma Source Direct

Address 8591 Prairie Trail Drive, Ste C-600
Englewood, CO 80112

Website www.pharmasd.com

Emergency phone number Infotrac: 1-800-535-5053

2. Hazard(s) Identification

Physical hazards	Not classified	
Health hazards	Acute toxicity, oral	Category 4
	Carcinogenicity	Category 1B
	Reproductive toxicity	Category 1
Environmental hazards	Not classified	
OSHA defined hazards	Not classified	

Label elements



Signal word Danger

Hazard statement Harmful if swallowed. May cause cancer. May damage fertility or the unborn child.

Precautionary statement

Prevention Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Wash thoroughly after handling. Wear protective gloves/protective clothing/eye protection/face protection.

Response If exposed or concerned: Get medical advice/attention. If swallowed: Call a poison center/doctor if you feel unwell. Rinse mouth.

Storage	Store locked up.
Disposal	Dispose of contents/container in accordance with local/regional/ national/international regulations.
Hazards not otherwise classified (HNOC)	Not classified.
Supplemental information	Pharmacologically active material.

3. Composition/Information on Ingredients

Substance

Chemical name	Common name and synonyms	CAS number	%
Testosterone Propionate		57-85-2	100

4. First-aid Measures

Inhalation	Move to fresh air. Call a physician if symptoms develop or persist.
Skin contact	Rinse skin with water/shower. Get medical attention if irritation develops and persists.
Eye contact	Rinse with water. Get medical attention if irritation develops and persists.
Ingestion	IF SWALLOWED: Call a POISON CENTER or doctor/physician if you feel unwell. Rinse mouth.
Most important symptoms/effects, acute and delayed	Not available.
Indication of immediate medical attention and special treatment needed	Symptoms may be delayed. Provide general supportive measures and treat symptomatically.
General Information	Remove from exposure. Remove contaminated clothing. For treatment advice, seek guidance from an occupational health physician or other licensed health-care provider familiar with workplace chemical exposures. In the United States, the national poison control center phone number is 1-800-222-1222. If person is not breathing, give artificial respiration. If breathing is difficult, give oxygen if available. Persons developing serious hypersensitivity (anaphylactic) reactions must receive immediate medical attention.

5. Fire-fighting Measures

Suitable extinguishing media	Use fire-extinguishing media appropriate for surrounding materials. Water. Foam. Dry chemical or CO2.
Unsuitable extinguishing media	None known.
Specific hazards arising from the chemical	No unusual fire or explosion hazards noted.

Special protective equipment and precautions for firefighters	Wear suitable protective equipment.
Fire fighting equipment/instructions	Use water spray to cool unopened containers. As with all fires, evacuate personnel to a safe area. Firefighters should use self-contained breathing equipment and protective clothing.
Specific methods	Use standard firefighting procedures and consider the hazards of other involved materials.

6. Accidental Release Measures

Personal precautions, protective equipment and emergency procedures	Keep unnecessary personnel away. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Ensure adequate ventilation. Avoid inhalation of dust from the spilled material. Wear appropriate personal protective equipment.
Methods and materials for containment and cleaning up	Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid the generation of dusts during clean-up. For waste disposal, see section 13 of the SDS. Clean surface thoroughly to remove residual contamination.

7. Handling and Storage

Precautions for safe handling	As a general rule, avoid all contact and inhalation of dust, mists, and/or vapors associated with the material. Clean equipment and work surfaces with suitable detergent or solvent after use. After removing gloves, wash hands and other exposed skin thoroughly. Use of a designated area is recommended for handling of potent materials.
Conditions for safe storage, including any incompatibilities	Preserve in well-closed, light-resistant containers.

8. Exposure Controls & Personal Protection

Occupational exposure limits	Not available.
Exposure limit values	
Biological limit values	No biological exposure limits noted for the ingredient(s)
Appropriate engineering controls	Airborne exposure should be controlled primarily by engineering controls such as general dilution ventilation, local exhaust ventilation, or process enclosure. Local exhaust ventilation is generally preferred to general exhaust because it can control the contaminant at its source, preventing dispersion into the work area. An industrial hygiene survey involving air monitoring may be used to determine the effectiveness of engineering controls. Effectiveness of engineering controls intended for use with highly potent materials should be assessed by use of nontoxic surrogate materials. Avoid any open handling of this material, particularly for grinding, crushing, weighing, or other dust-generating or aerosol-generating procedures. Use a laboratory fume hood, vented enclosure, glovebox, or other effective containment.

Individual protection measures, such as personal protective equipment

Eye/face protection	Safety glasses with sideshields are recommended. Face shields or goggles may be required if splash potential exists or if corrosive materials are present. Approved eye protection (e.g., bearing the ANSI Z87 or CSA stamp) is preferred. Maintain eyewash facilities in the work area.
Skin protection	
Hand protection	Chemically compatible gloves. For handling solutions, ensure that the glove material is protective against the solvent being used. Use handling practices that minimize direct hand contact. Employees who are sensitive to natural rubber (latex) should use nitrile or other synthetic nonlatex gloves. Use of powdered latex gloves should be avoided due to the risk of latex allergy. To reduce the risk of contamination of skin and surfaces, wear two pairs of gloves. Remove the outer gloves after handling and cleanup of the material, and remove the inner gloves only after removing other personal protective equipment.
Other	Train employees in proper gowning and degowning practices. Wear disposable lab coat, disposable sleeve covers and two pair of gloves, as appropriate for the task. Base the choice of skin protection on the job activity, potential for skin contact and solvents and reagents in use. Do not wear protective garments in common areas (e.g., cafeterias) or out-of-doors.
Respiratory protection	Use a powered air-purifying respirator (PAPR) with HEPA filters, disposable outerware and head cover for spill cleanup. Use NIOSH-approved respiratory protection and have an effective respirator program in place (applicable U.S. regulation OSHA 29 CFR1910.134). Chose respiratory protection appropriate to the task and the level of existing engineering controls.
Thermal hazards	Not available
General hygiene considerations	Handle in accordance with good industrial hygiene and safety practice.

9. Physical and Chemical Properties

Appearance	White or creamy white crystals or crystalline powder.
Physical state	Solid.
Form	Powder.
Color	White. Cream.
Odor	Odorless.
Odor threshold	Not available.
pH	Not available.
Melting point/freezing point	244.4 - 253.4 °F (118 - 123 °C)
Initial boiling point and boiling range	Not available.
Flash point	Not available.
Evaporation rate	Not available.
Flammability (solid, gas)	Not available.

Upper/lower flammability or explosive limits	
Flammability limit – lower (%)	Not available.
Flammability limit – upper (%)	Not available.
Explosive limit – lower (%)	Not available.
Explosive limit – upper (%)	Not available.
Vapor pressure	< 0.0000001 kPa at 25 °C
Vapor density	Not available.
Relative density	Not available.
Solubility(ies)	
Solubility (water)	Insoluble
Partition coefficient (n-octanol/water)	Not available.
Auto-ignition temperature	Not available.
Decomposition temperature	Not available.
Viscosity	Not available.
Other information	
Chemical family	Anabolic steroid.
Molecular formula	C22H32O3
Molecular weight	344.49

10. Stability and Reactivity

Reactivity	No reactivity hazards known
Chemical stability	Material is stable under normal conditions.
Possibility of hazardous reactions	No dangerous reaction known under conditions of normal use.
Conditions to avoid	None known.
Incompatible materials	Strong oxidizing agents.
Hazardous decomposition products	Irritating and/or toxic fumes or gases. Emits toxic fumes under fire conditions.

11. Toxicological Information

Information on likely routes of exposure

Ingestion	Harmful if swallowed.
Inhalation	Due to lack of data the classification is not possible.
Skin contact	Due to lack of data the classification is not possible.
Eye contact	Due to lack of data the classification is not possible.
Symptoms related to the physical, chemical, and toxicological characteristics	Anabolic steroids: Men and women: Swelling of feet and legs. Weight gain. Nausea. Vomiting. Diarrhea. Acne. Sleep disturbances. Bone or joint pain. Hair loss. Aggressive behavior. Mood swings. Headache. Men: Shrinking of testicles. Urinary difficulties. Breast enlargement or

	tenderness. Decreased sexual ability. Women: Growth of facial and body hair. Loss of breasts. Swelling of clitoris. Deep voice. Menstrual irregularities.
Delayed and immediate effects of exposure	Anabolic steroids: Liver toxicity. Water and sodium retention. Impaired glucose tolerance. Masculinization of females.
Cross sensitivity	Persons sensitive to one anabolic steroid or androgen may be sensitive to this material also.
Medical conditions aggravated by exposure	Anabolic steroids: Cardiovascular disorders. Kidney or liver impairment. Epilepsy. Migraine. Diabetes mellitus. Hypercalcemia. Sleep disorders. High cholesterol. Breast or prostate cancer (men).

Information on toxicological effects

Acute toxicity Harmful if swallowed.

Product	**Species**	**Test Results**
Testosterone Propionate (CAS 57-85-2))		
Oral		
LD50	Mouse	1350 mg/kg
	Rat	1000 mg/kg

Skin corrosion/irritation	Due to lack of data the classification is not possible.
Serious eye damage/eye irritation	Due to lack of data the classification is not possible.
Respiratory sensitization	Due to lack of data the classification is not possible.
Skin sensitization	Due to lack of data the classification is not possible.
Germ cell mutagenicity	Due to lack of data the classification is not possible. Data from germ cell mutagenicity tests were not found.
Carcinogenicity	May cause cancer. IARC: Group 2A; Probably carcinogenic to humans. In humans receiving long-term therapy with high doses of androgens, there were rare cases of hepatocellular carcinomas. Studies in mice given subcutaneous implants of testosterone showed an increase in cervical-uterine tumors. This effect was not seen in mice and rats given subcutaneous injections of testosterone or in rats given subcutaneous implants. Testosterone is also known to increase the number of tumors and decrease the degree of differentiation of chemically induced carcinomas of the liver in rats.
Reproductive toxicity	May damage fertility or the unborn child. Studies in humans have shown that androgens administered during pregnancy cause masculinization of the external genitalia of the female fetus; the degree of masculinization is dose related. In males, absent, low, or reduced sperm or sperm function resulting in possible infertility may occur during high-dose therapy with androgens. In females treated with androgens, the absence of menstruation may result, impairing fertility. Premature bone maturation and decreased birthweight have been reported with the use of anabolic steroids in humans.
Specific target organ toxicity - single exposure	Due to lack of data the classification is not possible.
Specific target organ toxicity - repeated exposure	Due to lack of data the classification is not possible.
Aspiration hazard	Based on available data, the classification criteria are not met.

12. Ecological Information

Ecotoxicity	No ecotoxicity data noted for the ingredient(s).
Persistence and degradability	No data is available on the degradability of this product.
Bioaccumulative potential	No data available.
Mobility in soil	No data available.
Other adverse effects	No data available.

13. Disposal Considerations

Disposal instructions	Dispose in accordance with all applicable regulations. Under RCRA, it is the responsibility of the user of the product to determine, at the time of disposal, whether the product meets RCRA criteria for hazardous waste.
Local disposal regulations	Not available.
Hazardous waste code	Not available.
Waste from residues / unused products	Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see: Disposal instructions).
Contaminated packaging	Empty containers should be taken to an approved waste handling site for recycling or disposal. Since emptied containers may retain product residue, follow label warnings even after container is emptied.

14. Transport Information

DOT

Not regulated as a hazardous material by DOT.

IATA

Not regulated as dangerous goods.

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code	No information available.

15. Regulatory Information

US federal regulations	CERCLA/SARA Hazardous Substances - Not applicable. All components are on the U.S EPA TSCA Inventory List.

Superfund Amendments and Reauthorization Act of 1986 (SARA)

Safety Data Sheet

Hazard categories	Immediate Hazard - Yes Delayed Hazard - No Fire Hazard - No Pressure Hazard - No Reactivity Hazard - No
SARA 302 Extremely hazardous substance	No
SARA 311/312 Hazardous chemical	No

Other federal regulations

Safe Drinking Water Act (SDWA)	Not regulated.
Drug Enforcement Administration (DEA) (21 CFR 1308.11-15)	Schedule III - 4000
Food and Drug Administration (FDA)	Not regulated.
US state regulations	WARNING: This product contains a chemical known to the State of California to cause birth defects or other reproductive harm.

International Inventories

Country(s) or region	Inventory name	On inventory (yes/no)*
Australia	Australian Inventory of Chemical Substances (AICS)	Yes
Canada	Domestic Substances List (DSL)	No
Canada	Non-Domestic Substances List (NDSL)	Yes
China	Inventory of Existing Chemical Substances in China (IECSC)	No
Europe	European Inventory of Existing Commercial Chemical Substances (EINECS)	Yes
Europe	European List of Notified Chemical Substances (ELINCS)	No
Japan	Inventory of Existing and New Chemical Substances (ENCS)	Yes
Korea	Existing Chemicals List (ECL)	Yes
New Zealand	New Zealand Inventory	Yes
Phillipines	Philippine Inventory of Chemicals and Chemical Substances (PICCS)	No
Unites States & Puerto Rico	Toxic Substances Control Act (TSCA) Inventory	Yes

*A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s)
A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).

Safety Data Sheet

16. Other Information

Disclaimer	The information in this SDS has been compiled from sources considered dependable, but has not been independently verified. The company cannot guarantee the accuracy of information herein, and the statements contained should not be considered an official expression. The company will not assume liability for any loss, damage, and/or expense resulting from the use and/or misuse of this product in regards to handling, storage, and/or disposal.
Issue date	20 Aug 2026
Version	1.0
Issued by	Pharma Source Direct – Quality Assurance